FDA’s Zetia/Vytorin Rejection Leaves Cholesterol Drug Sponsors In Limbo

FDA’s complete response letter for the cardiovascular risk reduction claim for Zetia/Vytorin was expected, but what will this mean for sponsors of drugs with other mechanisms, like PCSK9?